Last reviewed · How we verify
Norethindrone Acetate-Ethinyl Estradiol
At a glance
| Generic name | Norethindrone Acetate-Ethinyl Estradiol |
|---|---|
| Also known as | Estrogen-progestin, Ortho®-1/35 |
| Sponsor | Elizabeth Austen Lawson |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together (PHASE1)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
- Ovulation Incidence in Oral Contraceptive Users (PHASE3)
- Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive (PHASE1)
- International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
- Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers (PHASE3)
- Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: